Lenvatinib (new indication: endometrial carcinoma, after platinum-based therapy, in combination with pembrolizumab)

Subject:

• Active Substance: Lenvatinib
• Name: Lenvima^®
• Therapeutic area: Endometrial carcinoma
• Pharmaceutical company: Eisai GmbH

Time table:

• Start: 15.01.2022
• Final decision by G-BA: 07.07.2022

Final decision:

• Indication for a considerable additional benefit